Showing results (221-230 of 241) with videos related to

Sort By:
Pageof 25
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2019
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group StudyJoan L Walker, Mark F Brady, Lari Wenzel, et al.
Therapeutic Advances in Medical Oncology|September 30, 2024
Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)Annika Auranen, Matthew A Powell, Vladyslav Sukhin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2015
Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group StudyPaul J Goodfellow, Caroline C Billingsley, Heather A Lankes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2023
RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian CancerAmanda J Compadre, Lillian N van Biljon, Mark C Valentine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2024
Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial CarcinomaDaniela E Matei, Danielle M Enserro, Marcus E Randall, et al.
Gynecologic Oncology|May 26, 2026
Molecular classification and association with survival outcomes in high-intermediate and high-risk early-stage endometrial cancers: Ancillary analysis of GOG-0249Lindsay M Kuroki, Danielle M Enserro, Heather A Lankes, et al.
Cancer|December 8, 2016
Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group studyAbigail D Winder, Kruti P Maniar, Jian-Jun Wei, et al.
Gynecologic Oncology|May 29, 2026
Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trialMatthew A Powell, Henrik Roed, Lyndsay J Willmott, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 25, 2024
Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trialGiorgio Valabrega, Matthew A Powell, Sakari Hietanen, et al.
The Lancet. Oncology|August 30, 2024
Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroupCarien L Creutzberg, Jae-Weon Kim, Gemma Eminowicz, et al.
Pageof 25